REGENXBIO Inc. (RGNX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

REGENXBIO Inc. (RGNX) is down 53.5% since the beginning of the year. At $7 per share, RGNX is trading 58.7% below its 52-week high of $16. Investors who bought $1,000 worth of RGNX shares 5 years ago would now be looking at an investment worth $188.

REGENXBIO Inc. (RGNX) has returned -53.54% so far this year and -33.96% over the past 12 months. Over the last ten years, RGNX has returned -6.36% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Sep 17, 2015, RGNX's average daily return is +0.04%, while the average monthly return is +0.52%. At this rate, an investment would double in approximately 11.1 years.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2015 with a return of +55.1%, while the worst month was Jun 2016 at -35.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RGNX closed higher 49% of trading days. The best single day was Sep 13, 2021 with a return of +31.2%, while the worst single day was May 14, 2026 at -37.8%.

REGENXBIO Inc. has an annualized alpha of -9.86%, beta of 1.45, and R2 of 0.14 versus S&P 500 Index. Calculated based on daily prices since September 18, 2015.

• This stock participated in 157.75% of S&P 500 Index downside but only 47.15% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.14 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RGNX ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for REGENXBIO Inc. (RGNX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the REGENXBIO Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the REGENXBIO Inc. was 93.54%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current REGENXBIO Inc. drawdown is 91.86%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of REGENXBIO Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how REGENXBIO Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.